A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis
Topical Cannabidiol for Plantar Fasciitis: A Double-Blinded Study on Rapid and Sustained Pain Relief
調査の概要
詳細な説明
Plantar fasciitis is one of the most common causes of plantar heel pain, affecting millions of adults annually and accounting for a large proportion of musculoskeletal complaints seen in orthopaedic and sports medicine clinics. The condition is typically caused by repetitive microtrauma and inflammation at the plantar fascia's insertion on the calcaneus, leading to chronic pain, functional impairment, and limitations in daily activities. Despite its prevalence, effective and well-tolerated long-term treatments remain limited. Current management strategies, including stretching, orthotics, corticosteroid injections, and physical therapy, often provide only temporary relief or are associated with adverse effects from repeated use.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from hemp, has gained attention for its potential anti-inflammatory and analgesic properties. Preclinical and clinical studies have demonstrated CBD's ability to modulate inflammatory markers, reduce cytokine activity, and improve pain perception in various musculoskeletal and neuropathic conditions. These mechanisms make it a promising candidate for targeting inflammation-driven pain disorders such as plantar fasciitis. Although CBD has been studied for arthritis, tendon injuries, and generalized pain syndromes, no published trials have yet evaluated its efficacy in plantar fasciitis specifically.
A recent scoping review on topical CBD interventions confirmed this absence of evidence, highlighting a significant gap in the current literature regarding CBD's role in localized foot and heel pain. This lack of research underscores an unmet clinical need to assess whether transdermal delivery of CBD could provide measurable short- and long-term benefits in patients with plantar fasciitis.
This study aims to address that gap by evaluating a 6000 mg transdermal CBD cream (Tolcylen®, Marlinz Pharma) for both immediate and sustained pain reduction in adults with plantar fasciitis. By using a randomized, double-blinded, placebo-controlled design, we intend to determine whether topical CBD can offer a safe, non-invasive, and effective alternative or adjunct to current treatments. The results of this investigation may contribute to the emerging evidence on topical cannabinoids in orthopaedic pain management and inform future clinical practice guidelines.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Shea Herlihy, MS
- 電話番号:352-273-7361
- メール:herliso@ortho.ufl.edu
研究連絡先のバックアップ
- 名前:Antony Merendino, DPM
- 電話番号:352-273-7044
- メール:merena@ortho.ufl.edu
研究場所
-
-
Florida
-
Gainesville、Florida、アメリカ、32611
- University of Florida Department of Orthopaedics
-
コンタクト:
- Shea Herlihy, MS
- 電話番号:352-273-7361
- メール:herliso@ortho.ufl.edu
-
コンタクト:
- Antony Merendino, DPM
- 電話番号:352-273-7044
- メール:merena@ortho.ufl.edu
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Patients aged 18-85
- Clinical diagnosis of plantar fasciitis by a qualified provider
- Symptomatic for at least four weeks with plantar heel pain consistent with plantar fascia involvement
- Baseline average pain score that meets eligibility threshold as defined in the protocol (?)
- Willing to apply assigned cream once daily and attend needed visits (?)
Exclusion Criteria:
- Special populations and consent limitations. Pregnancy, breastfeeding, prisoners, inability to provide informed consent, or inability to complete study procedures
- Contraindications to topical products or CBD. History of allergy or sensitivity to cannabinoids, excipients, or topical creams used in the study
- Confounding dermatologic conditions at the application site. Open wounds, active infection, dermatitis, ulceration, or recent burns on the heel or midfoot
- Recent or planned procedures that alter outcomes. Corticosteroid injection, platelet rich plasma, surgery, immobilization, or shockwave therapy within the protocol washout window
- Concurrent therapies that confound pain outcomes. Routine use of systemic opioids, regular use of nonsteroidal anti-inflammatory drugs beyond rescue parameters, new analgesic starts during the study, or use of other topical analgesics on the study area
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Participants who receive a transdermal cannabidiol cream
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The active product is the study CBD cream supplied by the manufacturer.
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month.
The first dose will be taught and supervised in clinic using a glove.
The cream will be massaged into the affected area for at least forty-five seconds.
Skin must be clean and dry before application.
No other topical agents may be placed on the study area during the study period.
|
|
プラセボコンパレーター:Participants who receive a matched placebo
Dosing is three pumps per application which delivers approximately one point five milliliters of cream.
Application is once daily to the most tender plantar fascia region for the entire study month
|
The control group will receive a placebo cream identical in appearance, texture, scent, and packaging to the active product but containing no cannabidiol.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
• Immediate pain relief, measured by change in numeric rating scale (0-10) from baseline to ten minutes after supervised application.
時間枠:Daily for one month
|
Daily for one month
|
|
|
• One-month changes in average daily pain score compared to baseline.
時間枠:Daily for one month
|
Daily for one month
|
|
|
• Global patient satisfaction
時間枠:Daily for one month.
|
measured using a five-point Likert scale assessing overall perceived improvement.
|
Daily for one month.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of immediate pain relief following initial application
時間枠:Daily for one month
|
Daily for one month
|
|
|
Adherence to protocol measured by patient logs and pump counts
時間枠:Daily for one month
|
Daily for one month
|
|
|
Incidence of adverse effects
時間枠:Daily for one month
|
Occurrence of negative side effects
|
Daily for one month
|
|
Rescue analgesic use
時間枠:Daily for one month
|
Daily for one month
|
|
|
Time to perceived improvement in symptoms
時間枠:Daily for one month
|
Daily for one month
|
|
|
6. PROMIS Pain Interference questionnaire
時間枠:At enrollment and at end of once month
|
At enrollment and at end of once month
|
|
|
7. Foot Function Index questionnaires
時間枠:At enrollment and at one month
|
At enrollment and at one month
|
|
|
8. Return to normal activity - the number of days required for participants to resume full standing or walking tolerance without pain
時間枠:Once during one month
|
Once during one month
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。